These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25686120)

  • 21. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
    Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
    Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
    Alvarez RH; Kantarjian HM; Cortes JE
    Cancer; 2006 Oct; 107(8):1918-29. PubMed ID: 16986126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.
    Siveen KS; Prabhu KS; Achkar IW; Kuttikrishnan S; Shyam S; Khan AQ; Merhi M; Dermime S; Uddin S
    Mol Cancer; 2018 Feb; 17(1):31. PubMed ID: 29455667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.
    Vakili-Samiani S; Turki Jalil A; Abdelbasset WK; Yumashev AV; Karpisheh V; Jalali P; Adibfar S; Ahmadi M; Hosseinpour Feizi AA; Jadidi-Niaragh F
    DNA Repair (Amst); 2021 Nov; 107():103203. PubMed ID: 34390915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
    Milella M; Kornblau SM; Andreeff M
    Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer.
    Laczmanska I; Sasiadek MM
    Acta Biochim Pol; 2011; 58(4):467-70. PubMed ID: 22146137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF.
    Wang B; Lemay S; Tsai S; Veillette A
    Mol Cell Biol; 2001 Feb; 21(4):1077-88. PubMed ID: 11158295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.
    Gotlib J
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):643-661. PubMed ID: 28673393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
    Kim M; Baek M; Kim DJ
    Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tyrosine phosphorylation in cell growth and disease.
    Hunter T
    Harvey Lect; 1998-1999; 94():81-119. PubMed ID: 11070953
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent patents related to phosphorylation signaling pathway on cancer.
    Acosta KB; Tibolla MM; Tiscornia MM; Lorenzati MA; Zapata PD
    Recent Pat DNA Gene Seq; 2011 Dec; 5(3):175-84. PubMed ID: 21827380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
    Sun C; Duan P; Luan C
    Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New agents for solid tumours].
    Raida M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2407-10. PubMed ID: 17054057
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
    Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
    Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting oncogenic Ras signaling in hematologic malignancies.
    Ward AF; Braun BS; Shannon KM
    Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.